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Abstract
Background: Although entacavir and adefovir were widely used in most Asian countries, there were few conclusions
drawn from a meta-analysis for comparing the efficacy between entecavir and adefovir in nucleos(t)ide-naïve Asian
patients with chronic hepatitis B (CHB). The aim of this study was to evaluate the 48-week efficacy between the two
drugs in HBeAg-positive nucleos(t)ide-naïve Asian CHB patients with the method of Meta analysis, which was generally
accepted by the international as the best evidence for evaluating the efficacy of drugs.
Methods: We searched all data documented in Pubmed, Embase, Wanfang Database and CNKI (China National
Knowledge Infrastructure) before November 30, 2010. Heterogeneity was examined by Chi-square test, the relative
risk calculated and forest plot drawn. Rates of undetected serum HBV DNA, serum alanine aminotransferase (ALT)
normalization, HBeAg clearance and HBeAg seroconversion were analyzed. A total of 6 articles was included. Meta
analysis showed that the rate of undetected serum HBV DNA (relative risk, 1.73; 95% confidence interval, 1.38-2.17;
P < 0.00001) and that of serum ALT normalization (relative risk, 1.25; 95% confidence interval, 1.06-1.49; P = 0.009)
in the entecavir group were higher than those in the adefovir group. However, no statistic significance existed
between the two groups in the rate of HBeAg clearance (relative risk, 0.77; 95% confidence interval, 0.44-1.35; P =
0.36), or the rate of HBeAg seroconversion (relative risk, 0.74; 95% confidence interval, 0.28-1.94; P = 0.53).
Conclusions: Entecavir is superior to adefovir in decreasing serum HBV DNA and normalizing ALT but similar with
adefovir in clearing HBeAg and encouraging HBeAg seroconversion for the HBeAg-positive nucleos(t)ide-naive
Asian patients with chronic hepatitis B. Adefovir can be still used for first-line therapy in these patients.
1. Introduction
Infection with HBV is a major public health problem.
Approximately 2 billion people have been exposed to HBV,
and more than about 350 million are chronically infected
with HBV [1]. Chronic hepatitis B (CHB) can lead to life-
threatening conditions like liver cirrhosis (LC) and hepato-
cellular carcinoma (HCC) [2-4]. By the effective anti-HBV
therapy, the worsening progress may be blocked or delayed.
Oral nucleoside and nucleotide analogues (NAs) have revo-
lutionized the treatment of chronic hepatitis B, which can
suppress HBV replication in most patients and improve
transaminase levels. To date, three nucleoside analogues
(lamivudine, entecavir, telbivudine) and one nucleotide ana-
logue (adefovir) are approved for the treatment of HBV
infection in most of Asian countries. It can be confirmed
that NAs have exhibited powerful strength in improving
liver histology in most patients, however, two major short-
comings of NAs therapy frequently negate the benefits.
One is the high rate of virological relapse when treatment is
discontinued, and the other is the development of antiviral
drug resistance when treatment is administered in long
term [5]. Consequently, clinically relevant indicators for the
efficacy in therapy of chronic hepatitis B are often a drop in
circulating HBV DNA below detection level, clearance of
HBeAg, seroconversion from HBeAg to corresponding
anti-HBe antibodies, and normalization in serum ALT.
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evaluating the efficacy among these approved NAs in
nucleos(t)ide-naïve patients by Woo G [6]. The author
limited the literature search to the English language, and
did not classify the patients according to HBV endemic
regions. However, it was known to us, Asian CHB
patients possessed self-characteristics different from
western populations. For example, the durability of
hepatitis B e antigen responses after a period of therapy
is lower in Asian populations than that in western popu-
lations [7]. So, it was necessary to re-evaluate the effi-
cacy of NAs in Asian populations. Although entacavir
and adefovir were widely used in most Asian countries,
there are few conclusions drawn from a meta-analysis
for comparing the efficacy between entecavir and adefo-
vir in nucleos(t)ide-naïve Asian CHB patients. The aim
of study was to evaluate the 48-week efficacy between
the two drugs in HBeAg-positive nucleos(t)ide-naïve
Asian CHB patients with the method of Meta analysis,
which was generally accepted by the international as the
best evidence for evaluating the efficacy of drugs.
2. Data and methods
2.1 Literature Search
We searched Pubmed, Embase, Wanfang Database and
CNKI (National Knowledge Infrastructure) from the
date of inception until November 30, 2010. Of these
databases, Wanfang Database and CNKI provided litera-
tures in Chinese. In this study, the search was designed
using “entecavir”, “adefovir”, “chronic hepatitis B”, “lami-
vudine resistant or lamivudine refractory”. Reference
lists from retrieved documents were also searched.
2.2. Inclusion and exclusion criteria
All the following criteria were included: (i) study design:
randomized controlled trial; (ii) study population:
HBeAg-positive nucleos(t)ide-naïve Asian CHB patients
with HBeAg positivity; (iii) intervention: the doses of
entecavir and adefovir were respectively 0.5 mg/d and
10 mg/d, with the duration lasting 48 weeks.
The exclusion criteria were as follows: (i) non-human
studies; (ii) coinfection with hepatitis A, C, D, E,
Epstein-Barr virus, cytomegalovirus or HIV; (iii) coexis-
tence of any other liver diseases such as autoimmune
hepatitis, alcoholic liver disease, drug hepatitis or Wil-
son’s disease; (IV) liver transplantation; (V) past or cur-
rent hepatocellular carcinomas. Literatures with only
abstracts provided were also excluded.
2.3. Data extraction
Data were independently extracted from each study
using pre-defined forms by two investigators (Pan Z and
Weiwei L), and disagreement was resolved by discussion
among investigators and reference to the original article.
When several publications pertaining to a single study
were identified, the most complete publication was used.
The following information was extracted: the study
design (including random sequence generation, blind
method, and description of withdrawals and dropouts);
patient characteristics; number of cases and controls;
the concrete study results.
2.4. Efficacy measures and definitions
All outcome measurements were intermediate end
points taken at 48 weeks, because it is appreciated that
some patients would be continued or discontinued on
oral therapy beyond this time period. Data extracted
included rates of virological and biochemical response,
HBeAg clearance, and HBeAg seroconversion. Virologi-
cal response was defined as attainment of undetectable
levels of serum HBV DNA. Biochemical response was
defined as normalization of serum ALT. HBeAg clear-
ance was defined as HBeAg disappearance and HBeAg
seroconversion was defined as anti-HBe appearance.
2.5. Data analysis
Data analysis was carried out with the use of Review
Manager Software 4.2 (Cochrane Collaboration, Oxford,
United Kingdom). For each eligible study, dichotomous
data were presented as relative risk (RR), and both with
95% confidence intervals (CI). Meta-analysis was per-
formed using fixed-effect or random-effect methods,
depending on the absence or presence of significant het-
erogeneity. Statistical heterogeneity between trials was
evaluated by the chi-square and I-square (I
2)t e s t s .I n
the absence of statistically significant heterogeneity, the
fixed-effect method was used to combine the results.
When heterogeneity was confirmed (P < 0.05), the ran-
dom-effect method was used. The overall effect was
tested using Z scores, with significance set at P < 0.05.
3. Results
3.1. Characteristic and Quality of Studies
Of the 658 studies we identified in the search, 398 and 260
articles were published in English and Chinese, respectively.
After a review of the full texts, 652 articles were excluded
and 6 articles [8-13] (1 in English and 5 in Chinese) were
included based on the pre-specified criteria. One of the 6
articles written by Leung N et al, was a international multi-
center study and inevitably included non-Asian patients.
However, through inquisition into the detailed information
from related persons working in Bristol-Myers Squibb, we
confirmed that only minor non-Asian patients (12%) were
included in the study designed by Leung N et al [10], and
the number of these patients in ETV group was equal to
that in ADV group. So, we included this high-quality study
after discussion. The characteristics of the 6 clinical trials
included were shown in Table 1.
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In this analysis, 4 studies reported the rates of unde-
tected serum HBV DNA. According to chi-squared sta-
tistic and I square, heterogeneity was assessed and not
found to be a concern. Greater virological response
rates were observed in the entecavir group as compared
with that in the adefovir group, and the difference in
the rate between two groups were statistically significant
[105/161 vs. 54/148, RR = 1.73, 95%CI (1.38-2.17), P <
0.00001] (Figure 1).
3.3. Biochemical response
In this analysis, 4 studies reported the rates of serum
ALT normalization. According to chi-squared statistic
and I square, heterogeneity was assessed and not found
to be a concern. The biochemical response rates in the
entecavir group was higher as compared with that in the
adefovir group, and the difference in the rate between
two groups were statistically significant [93/131 vs. 76/
136, RR = 1.25, 95%CI (1.06-1.49), P = 0.009] (Figure 2).
3.4. HBeAg clearance
In this analysis, 5 studies reported the rates of HBeAg
clearance. According to chi-squared statistic and I
square, heterogeneity was assessed and not found to be
a concern. However, the difference in the rates of
HBeAg clearance at week 48 between the two groups
became similar, and no statistic significances existed
[17/152 vs. 21/154, RR = 0.77, 95%CI (0.44-1.35), P =
0.36] (Figure 3).
3.5. HBeAg seroconversion
In this analysis, 3 studies reported the rates of HBeAg
seroconversion. According to chi-squared statistic and I
square, heterogeneity was assessed and not found to be
a concern. However, the difference in the rates of
HBeAg seroconversion at week 48 between the two
groups were also similar, and no statistic significances
existed [6/101 vs. 8/106, RR = 0.74, 95%CI (0.28-1.94),
P = 0.53](Figure 4).
4. Discussion
Adefovir is an acyclic monophosphate adenine analogue
which was approved for the treatment of chronic hepati-
t i sBa tad o s eo f1 0m g / d a yi n2 0 0 2 .W o r l d w i d e ,t h e r e
have been an estimated 410,000 patient-years of adefovir
Table 1 Characteristic of the included studies
literature patient
races
study design
Ding H, 2005
[8]
Asian randomized controlled study with
description of withdrawals and dropouts
Zhang Q,
2009 [9]
Asian randomized controlled study with
description of withdrawals and dropouts
88% Asian
Leung N,
2009 [10]
12% non-
Asian
randomized controlled study with
description of withdrawals and dropouts
Yang F, 2010
[11]
Asian randomized controlled study with
description of withdrawals and dropouts
Zou S, 2010
[12]
Asian randomized controlled study with
description of withdrawals and dropouts
Huang H,
2010 [13]
Asian randomized controlled study with
description of withdrawals and dropouts
Figure 1 Forest plot-analysis of the 48-week virological response of entecavir therapy versus adefovir therapy.
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anti-HBV drugs in Asian countries, and this drug has
potent antiviral efficacy in nucleoside-naïve patients
with CHB, resulting in significant virological, biochem-
ical, and histological improvement [15-18]. A rando-
mized, double-blind, placebo-controlled, prospective
study conducted by Dong PL et al, showed that ADV
could effectively suppress HBV DNA and normalize
ALT at week 48 [19]. Entecavir is a carboxylic 2
’-deoxy-
guanosine analogue, and is approved in the US, EU and
many Asian countries [20]. The recommended once-
daily oral dosage of entecavir is 0.5 mg in nucleos(t)ide-
n a ï v ep a t i e n t s .I nt h eE T V - 0 2 3s t u d yc o n d u c t e di n
China, entecavir treatment provided better efficacy than
lamivudine at 48 weeks in terms of the composite
primary endpoint in a mixed population of HBeAg-posi-
tive or -negative patients [21].
In our study, we compared the efficacy between the
two drugs in suppressing HBV DNA, normalizing ALT,
clearing HBeAg and encouraging HBeAg seroconversion
with the method of meta-analysis, and found out that
for the HBeAg-positive nucleos(t)ide-naive Asian CHB
patients, ETV exhibited better efficacy than ADV at 48
weeks in suppressing HBV DNA and normalizing ALT,
however, in clearing HBeAg and encouraging HBeAg
seroconversion, the efficacy between the two drugs was
similar. It is a consensus that clearance of HBeAg and/
or development of anti-HBe are associated with
improved outcomes [22], so, for Asian population, ADV
treatment is not inferior to ETV treatment in all aspects
Figure 2 Forest plot-analysis of the 48-week biochemical response of entecavir therapy versus adefovir therapy.
Figure 3 Forest plot-analysis of the 48-week HBeAg clearance of entecavir therapy versus adefovir therapy.
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benefit in the long-term experience and safety, particu-
larly in Asian countries [23], it is confirmed that ADV
can be still used for first-line therapy in the HBeAg-
positive nucleos(t)ide-naive patients with CHB.
In conclusion, entecavir is superior to adefovir in
decreasing serum HBV DNA and normalizing ALT, but
similar with adefovir in clearing HBeAg and encoura-
ging HBeAg seroconversion for the HBeAg-positive
nucleos(t)ide-naive Asian patients with chronic hepatitis
B. Adefovir can be still used for first-line therapy in
these patients.
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